Search
- MediaPress Release
GSK’s Pazopanib significantly delayed tumor progression in patients with advanced kidney cancer
GSK announced results of a Phase III study - pazopanib reduced the risk of tumor progression or death by 54 percent compared to placebo.1
First published: 31 May 2009
- MediaPress Release
GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer
GSK announced submission of MAA to EMEA for pazopanib, oral therapy for metastatic renal cell carcinoma (RCC).
First published: 04 March 2009
- MediaPress Release
Regulatory update: Votrient® (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU
GSK today announced that it has withdrawn application to EMA for a variation to the Marketing Authorisation for Votrient® (pazopanib).
First published: 31 March 2014
- MediaPress Release
EU and US Regulatory Update - Votrient® (pazopanib)
GSK announced it's submitted a Marketing Authorisation Application to EMA for Votrient, the treatment of patients with advanced STR.
First published: 06 July 2011
- MediaPress Release
GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas
PALETTE study presented at ASCO demonstrated improvement in the time to occurrence of tumour progression in patients on pazopanib vs placebo
First published: 04 June 2011
- MediaPress Release
European Commission grants marketing authorisation for pazopanib (Votrient®) in the treatment of certain advanced soft tissue sarcoma subtypes
GSK announced today the EC has granted pazopanib marketing authorisation for the treatment of aSTS who have received prior chemotherapy.
First published: 07 August 2012
- MediaPress Release
GlaxoSmithKline receives conditional marketing authorisation in the EU for Votrient® (pazopanib)
As part of these conditions, GSK will provide data from ongoing clinical studies.
First published: 14 June 2010
- MediaPress Release
GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following chemotherapy in women with advanced epithelial ovarian cancer
GSK announced its Phase III trial of VOTRIENT met primary objective of a statistically significant improvement in PFS compared to placebo.
First published: 01 June 2013
- MediaPress Release
GSK receives positive opinions in Europe for Tyverb® (lapatinib) and Votrient™ (pazopanib)
GSK announced today that CHMP has issued two positive opinions in the European Union for two of its cancer medicines.
First published: 18 February 2010
- MediaPress Release
GSK receives positive opinion from European CHMP for pazopanib in the treatment of patients with certain advanced soft tissue sarcomas
GSK announced that the EMA CHMP has issued a positive opinion recommending marketing authorisation for Votrient for the treatment of STS.
First published: 25 May 2012